Compounders Research Compare

XBiotech Inc.(XBIT)

Biotechnology · Austin, TX

$2.17-0.02 (-0.69%)

Delayed quote: Oct 6, 2026, 3:30 PM EDT

About XBiotech Inc.

XBiotech Inc. is a biopharmaceutical firm specializing in the discovery, development, and commercialization of True Human monoclonal antibodies. Their primary focus involves building a robust pipeline of product candidates aimed at combating both inflammatory and infectious diseases. Furthermore, the company is advancing interleukin-1 alpha-based therapies, which are designed to address a broad spectrum of medical conditions such as cancer, stroke, heart attack, and arthritis. Interleukin-1 alpha itself plays a crucial role in biological processes like tissue breakdown, angiogenesis, blood clot formation, malaise, muscle wasting, and inflammation. Additionally, XBiotech is developing a True Human COVID-19 therapy specifically targeting mutant strains of the virus. Established in 2005, XBiotech Inc. maintains its headquarters in Austin, Texas.

Austin, TX

87 employees

www.xbiotech.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Sushma Shivaswamy

View full financials

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T19:38:43.704Z.

Stored calculation inputs

Calculation as of: 2026-10-06T19:38:43.704Z.

Quote observation: 2026-10-06T19:30:06.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 66,005,938
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 109,528,000
TTM operating EBITDA · period ending 2026-06-30: -46,783,000

FMP input reference: 4f0d9278b3abed9c67286a4c42ed3cbe71797fc66aa4bad88dc285e5ed2b1466

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

XBIT EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

XBIT Competitors' EV/EBITDA Ratio

XBiotech Inc.

Current

Market Cap

$66.01M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Cingulate Inc.

Market Cap

$66.47M

EV/EBITDA Ratio

0.23x

TTM Avg

0.03x

3Y Avg

0.03x

5Y Avg

0.03x

iBio, Inc.

Market Cap

$65.59M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Gossamer Bio, Inc.

Market Cap

$65.62M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Tiziana Life Sciences Ltd

Market Cap

$68.40M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Alps Group Inc

Market Cap

$63.56M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Fortress Biotech, Inc.

Market Cap

$68.10M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Spero Therapeutics, Inc.

Market Cap

$68.75M

EV/EBITDA Ratio

3.32x

TTM Avg

7.89x

3Y Avg

4.27x

5Y Avg

4.27x

Pliant Therapeutics, Inc.

Market Cap

$63.18M

EV/EBITDA Ratio

N/A

TTM Avg

29.74x

3Y Avg

29.74x

5Y Avg

29.74x

InterCure Ltd.

Market Cap

$63.02M

EV/EBITDA Ratio

N/A

TTM Avg

7.83x

3Y Avg

18.88x

5Y Avg

17.80x

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
XBiotech Inc. (XBIT)	$66.01M	N/A	N/A	N/A	N/A
Cingulate Inc. (CING)vs ›	$66.47M	0.23x	0.03x	0.03x	0.03x
iBio, Inc. (IBIO)vs ›	$65.59M	N/A	N/A	N/A	N/A
Gossamer Bio, Inc. (GOSS)vs ›	$65.62M	N/A	N/A	N/A	N/A
Tiziana Life Sciences Ltd (TLSA)vs ›	$68.40M	N/A	N/A	N/A	N/A
Alps Group Inc (ALPS)vs ›	$63.56M	N/A	N/A	N/A	N/A
Fortress Biotech, Inc. (FBIO)vs ›	$68.10M	N/A	N/A	N/A	N/A
Spero Therapeutics, Inc. (SPRO)vs ›	$68.75M	3.32x	7.89x	4.27x	4.27x
Pliant Therapeutics, Inc. (PLRX)vs ›	$63.18M	N/A	29.74x	29.74x	29.74x
InterCure Ltd. (INCR)vs ›	$63.02M	N/A	7.83x	18.88x	17.80x

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics